[ Price : $8.95]
Amgen reports positive results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected Stage ...[ Price : $8.95]
Former FDA district director John Scharmann says CDRHs plan to pilot pay-for third-party inspections in January is likely to be as...[ Price : $8.95]
Vertex Pharmaceuticals files a supplemental NDA for Kalydeco (ivacaftor) monotherapy for people with cystic fibrosis aged six and ...[ Price : $8.95]
CDER releases a draft guidance on ANDA Submissions ― Refuse-to-Receive Standards that describes what should be included in a...[ Price : $8.95]
Absent some miraculous compromise on Capitol Hill, it appears a government shutdown affecting almost half of FDA personnel is like...[ Price : $8.95]
FDA grants accelerated approval to Genentech for Perjeta (pertuzumab) and its use as part of a complete treatment regimen for pati...[ Price : $8.95]
CDRH denies a 2009 citizen petition from a private individual to force a recall of all Philips medical devices affected by Philips...[ Price : $8.95]
FDA approves a Takeda Pharmaceuticals and Lundbeck NDA for Brintellix (vortioxetine), indicated for treating adults with major dep...